TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis

Sepsis is a life-threatening syndrome induced by aberrant host response towards infection. The autophagy-lysosomal pathway (ALP) plays a fundamental role in maintaining cellular homeostasis and conferring organ protection. However, this pathway is often impaired in sepsis, resulting in dysregulated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xin Liu, Xinchuan Zheng, Yongling Lu, Qian Chen, Jiang Zheng, Hong Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	sepsis TFEB TFEB activators autophagy-lysosomal pathway inflammation immunity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4243e40015c64570a4b6cf66797b8dee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4243e40015c64570a4b6cf66797b8dee
record_format	dspace
spelling	oai:doaj.org-article:4243e40015c64570a4b6cf66797b8dee2021-12-01T07:19:04ZTFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis1663-981210.3389/fphar.2021.794298https://doaj.org/article/4243e40015c64570a4b6cf66797b8dee2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.794298/fullhttps://doaj.org/toc/1663-9812Sepsis is a life-threatening syndrome induced by aberrant host response towards infection. The autophagy-lysosomal pathway (ALP) plays a fundamental role in maintaining cellular homeostasis and conferring organ protection. However, this pathway is often impaired in sepsis, resulting in dysregulated host response and organ dysfunction. Transcription factor EB (TFEB) is a master modulator of the ALP. TFEB promotes both autophagy and lysosomal biogenesis via transcriptional regulation of target genes bearing the coordinated lysosomal expression and regulation (CLEAR) motif. Recently, increasing evidences have linked TFEB and the TFEB dependent ALP with pathogenetic mechanisms and therapeutic implications in sepsis. Therefore, this review describes the existed knowledge about the mechanisms of TFEB activation in regulating the ALP and the evidences of their protection against sepsis, such as immune modulation and organ protection. In addition, TFEB activators with diversified pharmacological targets are summarized, along with recent advances of their potential therapeutic applications in treating sepsis.Xin LiuXinchuan ZhengYongling LuQian ChenJiang ZhengHong ZhouFrontiers Media S.A.articlesepsisTFEBTFEB activatorsautophagy-lysosomal pathwayinflammationimmunityTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sepsis TFEB TFEB activators autophagy-lysosomal pathway inflammation immunity Therapeutics. Pharmacology RM1-950
spellingShingle	sepsis TFEB TFEB activators autophagy-lysosomal pathway inflammation immunity Therapeutics. Pharmacology RM1-950 Xin Liu Xinchuan Zheng Yongling Lu Qian Chen Jiang Zheng Hong Zhou TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
description	Sepsis is a life-threatening syndrome induced by aberrant host response towards infection. The autophagy-lysosomal pathway (ALP) plays a fundamental role in maintaining cellular homeostasis and conferring organ protection. However, this pathway is often impaired in sepsis, resulting in dysregulated host response and organ dysfunction. Transcription factor EB (TFEB) is a master modulator of the ALP. TFEB promotes both autophagy and lysosomal biogenesis via transcriptional regulation of target genes bearing the coordinated lysosomal expression and regulation (CLEAR) motif. Recently, increasing evidences have linked TFEB and the TFEB dependent ALP with pathogenetic mechanisms and therapeutic implications in sepsis. Therefore, this review describes the existed knowledge about the mechanisms of TFEB activation in regulating the ALP and the evidences of their protection against sepsis, such as immune modulation and organ protection. In addition, TFEB activators with diversified pharmacological targets are summarized, along with recent advances of their potential therapeutic applications in treating sepsis.
format	article
author	Xin Liu Xinchuan Zheng Yongling Lu Qian Chen Jiang Zheng Hong Zhou
author_facet	Xin Liu Xinchuan Zheng Yongling Lu Qian Chen Jiang Zheng Hong Zhou
author_sort	Xin Liu
title	TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
title_short	TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
title_full	TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
title_fullStr	TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
title_full_unstemmed	TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
title_sort	tfeb dependent autophagy-lysosomal pathway: an emerging pharmacological target in sepsis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/4243e40015c64570a4b6cf66797b8dee
work_keys_str_mv	AT xinliu tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis AT xinchuanzheng tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis AT yonglinglu tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis AT qianchen tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis AT jiangzheng tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis AT hongzhou tfebdependentautophagylysosomalpathwayanemergingpharmacologicaltargetinsepsis
_version_	1718405407249006592

TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis

Ejemplares similares